The results demonstrated that immunization with the GluN1356–385 peptide targeting the amino-terminal domain (ATD) of GluN1 effectively induced pathogenic anti-GluN1 antibodies and elicited characteristic symptoms of anti-NMDA receptor encephalitis (10), including cognitive dysfunction, social interaction deficits, and memory impairment (7, 10, 27). Here, GRIN1 is linked to memory impairment.